Prevention and the Long View

Prevention and the Long View

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief

Cardiovascular disease is the leading cause of death in women in the United States. Mortality has declined substantially over the past several decades. Contemporary guidelines now reflect sex-specific evidence far more explicitly than they did a generation ago. The progress has been substantial.

What remains is the conversation. Women’s cardiovascular prevention is not a single conversation at a single moment. It is a sequence of conversations across decades, each calibrated to what is biologically active at that life stage and what is documented in the woman’s accumulating cardiovascular history. The standard ten-year risk calculator is the starting point of that conversation in women, not its endpoint. Adverse pregnancy outcomes, premature or surgical menopause, autoimmune disease, chronic inflammation, microvascular dysfunction, and the syndromes that produce heart attacks without obstructed arteries are not captured by the calculator. The 2019 ACC/AHA primary prevention guideline addresses this through the risk-enhancing factors framework. (1) This article is the practical synthesis of what to do with the cumulative picture from the prior nine.

The Lifetime Risk Frame

Cardiovascular prevention is a long enterprise. Atherosclerosis begins in childhood and adolescence, accelerates through adulthood, and produces clinical events that in women concentrate in the postmenopausal decades. This framing matters because the prevention interventions most strongly supported by evidence are the ones that act on the multi-decade trajectory, not the ones that target the final years before clinical events.

In Framingham Heart Study data, the lifetime risk of coronary heart disease from age 40 is approximately 32 percent for women — substantial in absolute terms, even though lower than the approximately 49 percent lifetime risk for men. (2) One in three women alive at age 40 will develop coronary heart disease over her remaining lifetime. The risk that exists at age 50 has been substantially shaped by everything that preceded age 50. The risk that exists at age 70 will have been substantially shaped by what happens between 50 and 70.

This is the practical case for the early conversation. A 35-year-old woman with a history of preeclampsia, a positive family history, and a borderline lipid panel will not have a clinical cardiovascular event for many years. She is also living in the window during which prevention has the most leverage. The clinical conversation that incorporates her actual cardiovascular trajectory at 35 is more useful than the same conversation at 65. The cost of waiting is what the prior nine articles describe — disease that emerged from a trajectory the conventional pathway did not engage with early enough.

The Prevention Foundation

The foundation of cardiovascular prevention in women is the same foundation it is in men. The evidence base is large, durable, and consistent across decades. Five elements compose it.

Blood pressure. A primary modifiable cardiovascular risk factor in both sexes. Treatment thresholds and targets in current guidelines apply broadly. (1) Hypertension prevalence rises sharply in women after menopause and is a major driver of heart failure with preserved ejection fraction.

Lipids. Statin therapy is supported by extensive randomized evidence in women just as in men, with similar relative risk reductions. (1,3) The atherogenic lipid changes of the menopause transition and reproductive-year variability justify periodic re-evaluation across adult life. The 2018 ACC/AHA cholesterol guideline explicitly incorporates adverse pregnancy outcomes and premature menopause as risk-enhancing factors for cholesterol management decisions. (3)

Glucose and weight. Diabetes prevention and treatment are foundational; weight management is associated with major cardiovascular and metabolic benefit. Diabetes confers greater excess cardiovascular risk in women than in men, and the choice of diabetes medication is itself a cardiovascular decision in many women.

Physical activity and dietary pattern. Regular aerobic and resistance activity; dietary patterns emphasizing whole grains, vegetables, fruits, legumes, nuts, and fish, and limiting refined carbohydrates, processed meats, and added sugars. These recommendations apply broadly across both sexes.

Tobacco. Smoking cessation is the single intervention with the most consistent evidence for substantial cardiovascular benefit across both sexes. Smoking interacts multiplicatively with several female-specific factors — hormonal contraception, estrogen status, chronic inflammation. The combined risk is much greater than the sum of the individual risks.

These five elements are not new and not women-specific. What is women-specific is what comes next.

The Sex-Specific Prevention Elements

Four additional elements complete women’s cardiovascular prevention. Each is a category the conventional cardiovascular prevention conversation has historically addressed less completely, and each has been addressed in depth in the prior articles in this series.

Reproductive history. Preeclampsia, gestational hypertension, gestational diabetes, preterm delivery, and stillbirth carry cardiovascular implications that the 2021 American Heart Association scientific statement and the 2019 ACC/AHA primary prevention guideline formally incorporate. (1,4) The history does not change after the pregnancy events occur. What changes is whether the conversation it should produce actually happens. Documentation in the medical record in a way that makes the information retrievable for cardiovascular care decades later is the action that converts the history into modified care.

Menopause history. Age at menopause, surgical versus natural menopause, and the perimenopausal lipid and vascular changes inform cardiovascular risk in ways the calculator does not capture. (5) Premature menopause (before age 40) and early menopause (40–44) are formal risk-enhancing factors in current guidelines. The perimenopausal cardiovascular evaluation — lipid panel, blood pressure, glucose, weight, body composition — is the practical implementation.

Autoimmune and inflammatory history. Rheumatoid arthritis, systemic lupus erythematosus, and several other autoimmune conditions confer cardiovascular risk that conventional calculators do not capture. Active inflammation is itself a cardiovascular risk factor. Controlling disease activity is a cardiovascular intervention, not only a rheumatology one.

Persistent cardiac symptoms even after a normal angiogram. Microvascular disease, vasospastic disease, SCAD, and MINOCA each have specific evaluations. The “clean angiogram, you’re fine” framework has been demonstrated to miss meaningful cardiac pathology in women. If symptoms persist after a normal angiogram, the workup has not been completed.

A woman whose cardiovascular conversation engages all four of these elements is having a different conversation than one calibrated only to the calculator.

The Life Course Approach

A practical implementation of the framework involves the cardiovascular conversation being initiated and revisited at specific life stages where it has the most leverage.

In the reproductive years (roughly the 20s and 30s). Conventional risk factor screening — blood pressure, lipids, glucose, weight, smoking — starting in early adulthood, with attention to family history. Contraceptive method selection informed by the risk factor profile. Smoking cessation as a priority intervention. For most women in this window, the cardiovascular conversation is about establishing the baseline, identifying any inherited or early-onset risk factors, and making the contraception decision well.

During and after pregnancy. Documentation of any adverse pregnancy outcome — preeclampsia, gestational hypertension, gestational diabetes, preterm delivery, stillbirth — in a way that makes the information retrievable for cardiovascular care decades later. Postpartum cardiovascular risk factor screening, particularly after preeclampsia or gestational diabetes. The post-pregnancy years are a historically under-utilized prevention window. The risk signal from adverse pregnancy outcomes emerges measurably within the first decade postpartum, and earlier intervention has more time to alter the trajectory.

In the perimenopausal years (roughly the mid-40s through the early 50s). A focused cardiovascular evaluation that includes a lipid panel (with apolipoprotein B when available), blood pressure, glucose, weight, body composition, and review of the reproductive history. The atherogenic lipid changes around the final menstrual period are real and inconsistent with chronological aging alone. The perimenopausal years are the window during which the cardiovascular conversation has the most leverage and has historically been the most under-emphasized.

In the postmenopausal decades. Continued risk factor management with attention to the rising hypertension prevalence in older women, the integration of the accumulated history, and the syndromes more common after menopause. Cardiovascular event rates rise in this window, but the modifiability of risk factors does not decline correspondingly. Prevention continues to matter.

At and after a cardiovascular event. Secondary prevention — the management of cardiovascular risk factors after a clinical event — is foundational. The principles apply across both sexes. The implementation in women has historically been less consistent than in men, with documented disparities in statin prescribing, blood pressure control, and cardiac rehabilitation participation. A woman after a cardiovascular event should expect, and ask for, the same intensity of secondary prevention a man would receive.

What to Bring to the Visit

The translation of this framework into care depends on the conversation between a woman and her clinical team. Six questions are worth bringing into the next appointment, regardless of where a woman is in her life trajectory.

1. Given my reproductive history, menopause history, and any amplifying conditions — what is my actual cardiovascular risk picture, beyond what the standard calculator output gives?
2. If I have had preeclampsia, gestational diabetes, or another adverse pregnancy outcome — is that documented in a way that informs my cardiovascular care now? What should it change about my prevention plan?
3. If I am approaching, going through, or past menopause — has the perimenopausal cardiovascular evaluation happened, and is my prevention plan calibrated to my current trajectory?
4. Do any of my conditions — diabetes, autoimmune disease, chronic inflammation, postmenopausal hypertension, HIV — qualify as risk-enhancing factors under the 2019 ACC/AHA primary prevention guideline?
5. If I have had cardiac symptoms with a “normal” angiogram — has the workup been completed? Have microvascular disease, vasospastic disease, SCAD, or MINOCA been specifically considered?
6. What is my prevention plan — for blood pressure, lipids, glucose, weight, activity, diet, and tobacco — and is it calibrated to my actual risk profile, not just the calculator output?

These six questions, in whole or in part, can be brought into the next appointment as a checklist. Each one corresponds to a specific element this series has covered.

Putting This Into Practice

Three practical actions translate the framework into care.

The information should be in your medical record. Reproductive history, menopause timing, autoimmune diagnoses, family history of premature cardiovascular disease, any cardiac symptoms or workups, and the conditions discussed in Article 9 all belong in a place where they can inform cardiovascular care across decades. Information that exists only in obstetric notes, rheumatology notes, or remembered episodes does not reliably travel into the cardiovascular conversation. A medication list and a problem list that include this information is the operational version of “ownership of the cardiovascular risk picture.”

The cardiovascular risk picture needs an owner. A woman with a complex history — for example, diabetes, a previous preeclampsia, an autoimmune condition, perimenopausal — may have several specialists, none of whom owns the cardiovascular risk picture across all of her conditions. In practice, the cardiovascular conversation often does not happen unless someone asks for it. A primary care physician or cardiologist who explicitly takes ownership of the cardiovascular risk conversation across her conditions is a meaningful asset, and asking for that ownership directly is reasonable.

The framework is most useful before clinical events, not after. This is the lifetime risk insight. The cardiovascular conversation at 35 has more leverage than the same conversation at 65. A reader in her 30s, 40s, or 50s without diagnosed cardiovascular disease is in the window where prevention has the most leverage. The window is wide. The work it supports is consequential. The conversation does not need to wait.

The Bottom Line

The cardiovascular conversation in a woman’s life is not one conversation. It is a sequence of conversations across decades, each calibrated to what is biologically active at that life stage and what has accumulated in her history.

The conventional ten-year cardiovascular risk calculator is the starting point. It is not the endpoint. For a woman with adverse pregnancy outcomes, premature or surgical menopause, autoimmune disease, chronic inflammation, microvascular disease, or any of the conditions that disproportionately affect women — the calculator output alone does not reflect her actual cardiovascular trajectory. The risk-enhancing factors framework in current guidelines exists because calculator output alone undercounts risk in many women. (1) Using the framework converts a generic risk number into individualized care.

The work this series has tried to do is lay out, with clinical rigor and reader-facing voice, what women’s cardiovascular care looks like when it is calibrated to women’s actual biology, life course, and clinical presentation — rather than to a template designed around men. The work the reader can do, in her own care, is straightforward. Bring the relevant history into the conversation. Ask whether the conversation is happening at the right time and with the right elements. Recognize that the cardiovascular care she receives will substantially reflect what she brings into the visit and what she asks for.

Cardiovascular disease has been the leading cause of death in women in the United States for as long as the data have been kept. (6) The mortality decline of the past several decades reflects real progress. The progress that remains is the conversation — initiated earlier, returning regularly, calibrated to the woman’s actual trajectory rather than the average woman’s average risk score. This is what the contemporary evidence supports and what the contemporary guidelines recommend.

The cardiovascular conversation in women’s lives is the conversation worth having. The framework to support it exists. The next step is using it.

This is the final article in the Women’s Cardiovascular Health Series. The series focused on adult women and on coronary heart disease, stroke, and related vascular events. Several specific conditions — atrial fibrillation, valvular heart disease, peripheral artery disease, peripartum cardiomyopathy, congenital heart disease in adults — were not covered in depth and warrant their own dedicated treatment.

Key Terms

Atherogenic lipoprotein: A lipoprotein particle that contributes to the formation of atherosclerotic plaque. Includes low-density lipoprotein and several other apolipoprotein B–containing particles.

Cardiovascular disease (CVD): Diseases of the heart and blood vessels, including coronary heart disease, stroke, heart failure, and peripheral artery disease. The leading cause of death in women in the United States.

Life course approach: A framework for cardiovascular prevention that recognizes risk accumulating across decades and prevention interventions having different leverage at different life stages.

Lifetime risk: The probability that an individual will develop a specified condition over the remainder of their life from a given starting age. For coronary heart disease beginning at age 40, lifetime risk is approximately 32 percent in women and 49 percent in men.

Primary prevention: Cardiovascular interventions in individuals without established cardiovascular disease, directed at preventing the first clinical event.

Risk-enhancing factor: A term from the 2019 ACC/AHA primary prevention guideline for factors beyond the standard risk calculator inputs that may justify reclassifying cardiovascular risk. Includes adverse pregnancy outcomes, premature menopause, autoimmune diseases, persistently elevated hs-CRP, HIV/AIDS, chronic kidney disease, metabolic syndrome, and several other conditions.

Secondary prevention: Cardiovascular interventions in individuals with established cardiovascular disease, directed at preventing recurrence and progression.

Sex-specific cardiovascular risk factors: Factors that affect cardiovascular risk and either occur only in women, occur much more frequently in women, or operate differently in women than in men. Includes adverse pregnancy outcomes, premature and early menopause, several autoimmune diseases, and the conditions and syndromes covered throughout this series.

Ten-year risk: The calculated probability of a major cardiovascular event over the next ten years, used in major prevention guidelines to inform decisions about pharmacologic prevention.

References

1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):e177–e232.
2. Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet.1999;353(9147):89–92.
3. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350.
4. Parikh NI, Gonzalez JM, Anderson CAM, et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. Circulation. 2021;143(18):e902–e916.
5. El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation.2020;142(25):e506–e532.
6. Palaniappan LP, Allen NB, Almarzooq ZI, et al. 2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2026;153(9):e275–e906.